Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

254P - Is the watch-and-wait strategy appropriate in locally advanced rectal cancer patients with clinical T4 tumors?

Date

27 Jun 2024

Session

Poster Display session

Presenters

Hanna Kakish

Citation

Annals of Oncology (2024) 35 (suppl_1): S106-S118. 10.1016/annonc/annonc1480

Authors

H.H. Kakish1, R. Hoehn1, A. Mahipal2, S. Chakrabarti3

Author affiliations

  • 1 UHSeidmanCancerCenter, Cleveland/US
  • 2 University Hospitals Cleveland Medical Center, Cleveland/US
  • 3 University Hospitals Seidman Cancer Center, Cleveland/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 254P

Background

The watch-and-wait (WW) strategy has become increasingly adopted in the management of locally advanced rectal cancer (LARC), extending even to patients with clinical T4 (cT4) tumors. However, the efficacy and safety of this approach in patients with cT4 LARC, who face increased risks of both local and distant recurrences, lack substantial supporting data.

Methods

LARC patients with cT4 tumors were selected from the US National Cancer Database (2010-2020), comparing outcomes with surgical (Sx) versus non-surgical (NOM) treatment. Inclusion criteria: age 18-65 years, Charlson comorbidity index (CCI) 0 or 1, cT4cN+/- rectal cancer, receipt of neoadjuvant multi-agent chemotherapy, and radiation ≥ 45 Gray. These criteria aimed to reflect real-world scenarios of patients pursuing the WW strategy. Overall survival (OS) was compared between Sx and NOM cohorts using Kaplan-Meier methodology, both overall and after propensity score matching. Additionally, a multivariable Cox proportional hazard model was employed to explore the association between NOM and OS in the entire cohort.

Results

The analysis included 2,402 patients, of whom 2,071 (86.2%) underwent surgery. The median age was 54 years, with a predominant representation of non-Hispanic White individuals (73.2%), Charlson-Deyo scores of 0 (85.2%), and private insurance coverage (61.6%). The majority received treatment at academic (38.0%) or comprehensive community (29.4%) cancer centers. Patients in the NOM cohort demonstrated significantly lower OS compared to those undergoing surgery, with a 5-year OS rate of 44.5% (95% confidence interval [CI], 37.0-51.8) versus 72.5% (95% CI, 69.9-74.8; p < 0.001). NOM was associated with a median OS of 51.4 months (95% CI, 43.4-67.2) versus 131.5 months (95% CI, 122.4-not reached) in the Sx group (p < 0.001). These findings persisted in propensity score-matched analysis. Finally, multivariable regression analysis revealed NOM to be significantly associated with worse OS than Sx (Hazard Ratio, 2.73; 95% CI, 2.24-3.32).

Conclusions

In patients with LARC and cT4 tumors, a non-surgical strategy appears to confer significantly inferior overall survival compared to surgery.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.